Botulinum toxin type A vs placebo
Number of migraine days per month: chronic migraine only · adults with migraine
1 finding from 1 review
- no estimate extracted4 studies · 1497 participantsLow
The review found no eligible studies for this question.
It is very uncertain whether botulinum toxin type A changes total number of participants experiencing an adverse event compared with other established prophylactic agent (very low certainty).
Botulinum toxin type A probably leads to higher total number of participants experiencing an adverse event compared with placebo (moderate certainty).